The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 09, 2025

Filed:

Jul. 29, 2020
Applicant:

University of Pittsburgh—of the Commonwealth System of Higher education, Pittsburgh, PA (US);

Inventors:

Steven R. Little, Pittsburgh, PA (US);

Giorgio Raimondi, Pittsburgh, PA (US);

Angus W. Thomson, Pittsburgh, PA (US);

Siddharth Jhunjhunwala, Chennai, IN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/16 (2006.01); A61K 31/203 (2006.01); A61K 31/436 (2006.01); A61K 38/18 (2006.01); A61K 38/20 (2006.01); A61K 38/22 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 9/16 (2013.01); A61K 9/1635 (2013.01); A61K 9/1641 (2013.01); A61K 9/1647 (2013.01); A61K 9/1658 (2013.01); A61K 31/203 (2013.01); A61K 31/436 (2013.01); A61K 38/1841 (2013.01); A61K 38/2013 (2013.01); A61K 38/2278 (2013.01); A61K 39/0008 (2013.01); A61K 39/001 (2013.01);
Abstract

The absence of regulatory T cells (Treg) may underlie disorders including but not limited to autoimmunity, dermatitis, periodontitis and even transplant rejection. Enhancing local numbers of Treg through in situ Treg expansion or induction is contemplated herein as a treatment option for these disorders. Current methods for in vivo Treg expansion are not Treg specific and are associated with many adverse side-effects. The data presented herein provides in vitro testing of a Treg-inducing microparticle providing a predictable controlled release for combinations of cytokines and drugs (e.g., IL-2, TGF-β, and/or rapamycin) resulting in targeted Treg migration. These controlled release microparticles are also capable of inducing FoxP3+ Treg in human cells in vitro suggesting that these compositions be developed into an in vivo Treg induction and expansion therapy.


Find Patent Forward Citations

Loading…